Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.

Amir Abbas Tahami MonfaredWeicheng YeAditya SardesaiHenri FolseAmeya ChavanKang KangQuanwu Zhang

Published in: Neurology and therapy (2023)

The economic study suggested that lecanemab plus SoC would improve health and humanistic (quality of life) outcomes and reduce economic burden for patients and caregivers in early AD.

Keyphrases

end stage renal disease
ejection fraction
public health
newly diagnosed
healthcare
chronic kidney disease
peritoneal dialysis
palliative care
cognitive decline
risk assessment
metabolic syndrome
climate change
insulin resistance